"Institut de Cancérologie Lucien Neuwirth Service pharmacie-Essais cliniques"
Welcome,         Profile    Billing    Logout  
 3 Trials 
3 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Jacquin, Jean-Philippe
PELICAN, NCT03515798 / 2016-001868-11: Study of Immunotherapy in Combination With Chemotherapy in HER2-negative Inflammatory Breast Cancer

Checkmark PELICAN-IPC 2015-016/Oncodistinct-003: A Prospective, Multicenter, Open-Label, Randomized, Non-Comparative, Phase II Study of Pembrolizumab in Combination With Neo Adjuvant EC-Paclitaxel Regimen in HER2-Negative Inflammatory Breast Cancer.
Checkmark A prospective, multicentre, open-label, randomized phase II study of PEmbroLizumab in combination with neo-adjuvant (F)EC-paclitaxel regimen in HER2-negative Inflammatory breast CANcer
Recruiting
2
81
Europe
Pembrolizumab Injection, MK3475, neoadjuvant EC-paclitaxel chemotherapy, Epirubicine, Cyclophosphamide, Paclitaxel
Institut Paoli-Calmettes, MSD France, Oncodistinct
Inflammatory Breast Cancer
12/20
04/25
BREASTIMMU02, NCT03571633 / 2017-002069-22: Impact of Pegfilgrastim on Trastuzumab Anti-tumor Effect and ADCC in Operable HER2+ Breast Cancer Breast Cancer

Recruiting
2
90
Europe
Trastuzumab + Paclitaxel, Pegfilgrastim, Neulasta
Centre Leon Berard, Amgen
HER2-positive Breast Cancer, Operable Breast Cancer
04/22
04/22
NCT03840213: Nutrition and Chemotherapy

Not yet recruiting
N/A
200
Europe
Filling a questionnaire and interviewDescription
Institut de Cancérologie de la Loire, Ligue contre le cancer, France
Cancer
12/19
09/20
FAVRE, Pauline
No trials found

Download Options